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S U P P L E M E N T A R T I C L E
Epidemiology and Management of Infections
after Lung Transplantation
Rudolf Speich1 and Wim van der Bij2
1Department of Internal Medicine, University Hospital, Zurich, Switzerland; and 2Department of Pulmonology, University Hospital, Groningen,
The Netherlands
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascular
diseases. Infections still are the most common cause of early and late morbidity and mortality in lung transplant
recipients. Bacterial infections comprise approximately half of all infectious complications. Cytomegalovirus
(CMV) infections and disease have become less frequent, because of prophylaxis with ganciclovir. Because
CMV is also involved in the pathogenesis of obliterative bronchiolitis, the frequency of this infection may
also reduce the occurrence of this main obstacle to successful lung transplantation. Invasive fungal infections
remain a problem, but they have also decreased in frequency because of better control of risk factors such as
CMV disease and preemptive antifungal therapy. Nonherpes respiratory viral infections have emerged as a
serious problem. Their severity may be reduced by treatment with ribavirin. Meticulous postoperative sur-
veillance, however, is still crucial for the management of lung transplant patients with respect to early detection
and treatment of rejection and infection.
Lung transplantation has become a successful treatment
option for end-stage diseases of the lungs and the pul-
monary circulation [1, 2]. According to the registry of
the International Society for Heart and Lung Trans-
plantation, 1-, 2-, and 5-year survival rates of 74%,
65%, and 47%, respectively, can be achieved [3]. This
success is mainly due to careful selection of patients,
improved surgical techniques, and organ preservation,
as well as sophisticated postoperative management. The
most important complications in survivors of the peri-
operative period of lung transplantation are infections
and episodes of acute rejection. The main obstacle to
long-term success of lung transplantation, however, re-
mains chronic rejection, which occurs in up to two-
thirds of patients [4]. It is characterized histologically
by obliterative bronchiolitis and a variable degree of
pulmonary vascular involvement. In addition to the
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number of previous acute rejection episodes and the
incidence of persistent rejection after treatment of acute
rejection episodes [4], cytomegalovirus (CMV) infec-
tion and disease [5] are the most relevant risk factors
for the development of obliterative bronchiolitis. Thus,
strategies for prophylaxis, as well as early diagnosis and
treatment of CMV disease, may be crucial for further
improvement of the results of lung transplantation.
Infectious complications are the most common cause
of morbidity and mortality at all time points after lung
transplantation [6–11] and occur twice as frequently as
in heart transplant recipients [7, 9]. At least two-thirds
of the infections involve the respiratory tract [8–10].
Infectious complications cause at least half of the deaths
after lung transplantation, and more than one-third of
these fatal outcomes occur in patients with underlying
obliterative bronchiolitis [12]. Possible reasons for this
very high incidence of infectious complications are
listed in table 1 and include an allograft exposed con-
tinuously to the environment, impaired mucociliary
clearance, bronchial anastomotic problems, and re-
maining native lung complications after single-lung
transplantation. The most important predisposing con-
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Table 1. Conditions predisposing for infections after lung transplantation.
Lung allograft is continuously exposed to the external environment
Denervation of allograft:
Diminished cough reflex
Abnormal mucociliary clearance
Reactive hyperresponsiveness
Interrupted lymphatic drainage (especially during first weeks)
Anastomosis site:
May enhance colonization
Airway dehiscence and mediastinitis
Bronchial stenosis and postobstructive infection
Acute rejection episodes:
Require enhanced immunosuppression
Inflammatory response at port of entry of infections
Donor lung may transmit infections:
From prolonged mechanical ventilation
From previous inactive infections (tuberculosis, Candida and Aspergillus species, Histoplasmosis, Coccimycosis)
Native lung after single-lung transplantation:
Occult pretransplant infection (tuberculosis, Aspergillus species, Pneumocystis carinii, etc., especially after
immunosuppression before transplantation)
Posttransplant infections in destroyed lung
Sinus infection in cystic fibrosis and ciliary dysfunction syndromes
Bronchiolitis obliterans:
Enhanced immunosuppression
Impaired clearance
Bronchiectasis
dition, however, is obliterative bronchiolitis. These patients
usually are profoundly immunosuppressed, and their lung
function and mucus clearance are often markedly impaired.
Therefore, the most common cause of death in patients suf-
fering from obliterative bronchiolitis is infections [4].
EPIDEMIOLOGY AND PREVENTION
Bacterial pneumonias are the most frequent infectious com-
plications after lung transplantation. The reported incidences
of bacterial pneumonia range from 35% to 66% [8, 10, 13, 14].
A significant number of the early episodes of bacterial pneu-
monia are caused by microorganisms cultivated from the donor
lungs, as discussed below. Because their incidence during the
first 2 postoperative weeks has decreased markedly because of
antibiotic prophylaxis, most bacterial pneumonias occur in the
intermediate and late postoperative period [13]. The overall
cumulative incidence during the first year after transplant is
∼70%, and it remains high beyond the first year (30%–40%).
Nearly three-quarters of all bacterial pneumonias are caused
by Pseudomonas species and Enterobacteriaceae [6, 7, 9, 13],
and the remainder primarily by Staphylococcus aureus, Enter-
ococcus species, and Hemophilus influenzae.
Infections by Mycobacterium tuberculosis are occasionally re-
ported [15–18]. They may be due to reactivation [15], occult
disease in the remaining native lung after single-lung trans-
plantation [19], or transmission by the transplant [16–18]. One
single case of nosocomial tuberculosis in a lung transplant re-
cipient has been described [15]. Atypical mycobacteria are
rarely found after lung transplantation [20, 21]. They usually
present as indolent disease and respond well to treatment. One
case of a fatal infection with Mycobacterium chelonae in a patient
with severe obliterative bronchiolitis has been reported [21].
The second most common infectious complication after lung
transplantation is CMV disease. The reported incidence in
larger series ranges between 53% and 75% [22–25]. Thus, the
occurrence of CMV infection and disease is much higher in
lung transplant patients than in other solid-organ recipients.
The rate of CMV pneumonitis is high not only in the D/R
patients (90%–100%) but—in contrast to other solid-organ
transplantations—also in the D/R patients, in whom the
incidence of severe disease is ∼60%. Fatal cases are not rare.
Thus, an effective prophylaxis of this disastrous complication
is highly warranted (see article by van der Bij and Speich [26],
in this issue).
Herpes simplex virus (HSV) infections after lung transplan-
tation are of special concern [10, 27, 28]. The incidence of HSV
infections is up to 18% [27, 28]. Most infections are clinically
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significant [27]. Severe HSV pneumonia occurs in ∼10% of
patients without prophylaxis. The fatality rate is 20% [10, 28].
Most infections are due to reactivation and may occur as early
as 5–10 days after transplantation. Single cases of primoinfec-
tion are described after renal transplantation. Prophylaxis with
acyclovir reduces the incidence of HSV infections in immu-
nosuppressed patients [29], and valacyclovir may even be su-
perior. Thus, lung transplant recipients should receive 1 of these
drugs for ∼3 months postoperatively (A-II), if not already being
treated with ganciclovir.
The incidence of Epstein-Barr virus (EBV)–related posttran-
splant lymphoproliferative disorders after lung transplantation
varies greatly and ranges from 2% to 33% [11, 30–32]. In most
cases, the disease originates in the lung allograft [30, 31]. None-
theless, restriction fragment–length polymorphism analysis has
shown that the neoplastic cells usually arise from the recipient’s
lymphocytes [33]. The risk for the development of posttran-
splant lymphoproliferative disorders is higher in EBV-negative
lung transplant recipients [30], patients transplanted for cystic
fibrosis [31], and recipients of lungs from donor with human
leukocyte antigen status A2 and DR7 [32]. For further details,
see article by Preikasaitis and Keay [34], in this issue.
The role of other viruses is not yet clear but may be relevant.
Some centers have found a high incidence of nonherpes res-
piratory viruses [27, 35]. The attack rate, however, is !5% in
most series. Rhinovirus infection sometimes causes mild upper
respiratory tract disease in pediatric lung transplant recipients
[36], but most cases are asymptomatic [27]. No permanent loss
of respiratory function has been seen [27, 36]. Parainfluenza
virus infections with significant pulmonary involvement and
promotion of obliterative bronchiolitis have been described [27,
35, 36]. There is only 1 report of a severe influenza virus pneu-
monia in a pediatric lung transplant recipient who was treated
with amantadine and recovered, but later developed obliterative
bronchiolitis [37]. Respiratory syncytial virus infections in lung
transplant recipients are often asymptomatic [27, 38]. They may
cause, however, mild respiratory illness particularly in the pe-
diatric patients [35, 36]. Ground-glass opacities are seen in
almost 70% of the patients [39]. Cases with severe pneumonia
and recovery in about one-third of them after treatment with
aerosolized ribavirin have been reported [35, 40–42]. Oblit-
erative bronchiolitis develops in about half of the survivors [9,
39, 42]. Infection with adenovirus poses a serious problem in
the pediatric lung transplant recipients [36]. The attack rate is
almost 50%, and at least half of the patients die in respiratory
failure because of diffuse alveolar damage induced by the virus
[36]. Obliterative bronchiolitis develops uniformly in the sur-
vivors. Occasional cases of adults with adenovirus infections
are documented [27, 42–44]. In most of them, the clinical
course was fatal [38, 42–44]. The 4 survivors all developed
obliterative bronchiolitis [27, 42]. Cases of donor-transmitted
adenoviral infections have been described [36]. In conclusion,
nonherpes viral respiratory infection may be serious in lung
transplant recipients, causing respiratory failure and obliterative
bronchiolitis in the survivors. With respect to the various case
reports and in analogy to the promising results in bone marrow
transplant recipients [45, 46], we recommend treatment with
ribavirin, either oral, iv, or aerosolized, in cases with significant
nonherpes viral respiratory tract infections (B-III).
Fungal infections still are common in lung transplant recip-
ients. Colonization with Aspergillus species occurs in 22%–85%
of lung transplant recipients at some time after transplantation
[47–54]. There is no difference in frequency of postoperative
colonization between patients with cystic fibrosis, who often
harbor Aspergillus species in their airways before transplanta-
tion, and the recipients without cystic fibrosis [50, 51, 55].
Invasive aspergillosis occurs in 13%–26% of the colonized lung
transplant recipients and is uniformly fatal [53, 54]. Some pa-
tients develop invasive disease without prior colonization [48].
The risk of invasive aspergillosis peaks within the first 6 post-
operative months, but at least one-third of the cases occur later
[48]. Invasive aspergillosis may arise in the native lung after
single-lung transplantation, either immediately after transplant
because of preexistent disease in pretransplant immunosup-
pressed recipients [19] or in patients with destroyed native
lungs (emphysema, lymphangioleiomyomatosis) [8, 19, 51,
56–58]. Native lung pneumonectomy is advisable in the latter
(B-III) [56]. Patients suffering from obliterative bronchiolitis
are also predisposed to the occurrence of invasive aspergillosis
[12, 51]. A semi-invasive form of aspergillosis involving the
anastomosis site and the large airways is quite common in lung
transplant recipients [47, 49, 54, 59]. Treatment with either
amphotericin B or itraconazole is successful in most cases. Col-
onization with Aspergillus species and previous CMV disease
are significant risk factors for the development of invasive as-
pergillosis [48, 54]. Both conditions portend a relative risk of
11 for invasive disease [48, 54]. Preemptive therapy of colonized
patients with oral itraconazole is highly recommended (A-II)
and may completely prevent the development of invasive dis-
ease [49]. Semi-invasive tracheobronchial aspergillosis may de-
velop despite treatment and can be cured by increasing the
itraconazole dosage up to 400 mg b.i.d., with the goal of serum
levels 11000 mg/L [49]. In 2 studies comparing a historical
control group with patients treated with inhaled amphotericin
B up to 20 mg t.i.d., the cumulative incidence of infections
with Aspergillus species could be reduced significantly [60].
Whereas one report did not specify the rate of infection and
disease, the second group found a decrease in the incidence of
invasive aspergillosis from 15% (2/13 patients) to 0 (52 patients;
). Thus, primary prophylaxis with inhaled amphoter-Pp .038
icin B may be considered in lung transplant recipients (B-II).
Most invasive infections with Candida species occur during
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the first postoperative month, and most of them are transmitted
via the donor organ (see below). The most common presen-
tations are candidemia [61], necrotizing bronchial anastomotic
infection [62], mediastinitis [14], and aortic anastomotic in-
fection and disruption after heart-lung transplantation [63].
The incidence of Pneumocystis carinii pneumonia varies
greatly between centers [6, 7, 64, 65]. A prevalence of up to
88% has been described in patients not receiving prophylaxis
[64]. About two-thirds of the episodes are detected in asymp-
tomatic patients by routine bronchoscopy and bronchoalveolar
lavage. The organisms may stem from the recipient in cases
with pretransplant immunosuppression. Prophylaxis with co-
trimoxazole is nearly 100% effective [9, 11, 65] and therefore
highly recommended (A-I). Inhaled pentamidine may be an
alternative in patients not tolerating sulfa drugs (B-III). About
one-third of the infections with P. carinii may occur after the
first postoperative year [65]. Therefore, life-long prophylaxis is
recommended by many centers (B-II), or, if discontinued, pro-
phylaxis should be reinstituted in any patient receiving aug-
mented immunosuppression (B-II).
Toxoplasma gondii pneumonitis has been described exclu-
sively in heart-lung recipients [66]. There was 1 case of reac-
tivation and 1 of primoinfection; both were diagnosed serol-
ogically, but not biopsy-proven. So far, no cases have been
reported in recipients of lung transplants.
DIAGNOSTIC CONSIDERATIONS
Lung transplant recipients with fever or any organ dysfunction
should undergo aggressive diagnostic work-up [2]. Blood cul-
tures should be obtained routinely (A-II), because up to 25%
of patients suffer from bloodstream infections during the early
or late postoperative course [61]. S. aureus, Pseudomonas aeru-
ginosa, and Candida species are the most common bloodstream
isolates. In patients with respiratory symptoms or signs, bron-
choscopy, bronchoalveolar lavage, and transbronchial lung bi-
opsy should be performed immediately (A-II). Its diagnostic
yield is almost 70% [67]. Inspection of the airways may reveal
anastomotic problems or tracheobronchial aspergillosis. Bron-
choalveolar lavage is very sensitive for most pathogens. Trans-
bronchial biopsy is the only means to diagnose acute rejection
and CMV pneumonitis [68–70]. Its sensitivity and specificity
is almost 100%. Computed tomography may be helpful in the
differential diagnosis of bilateral infiltrative lung diseases and
detect mediastinal, bronchial, or vascular complications [71].
Most centers now perform routine surveillance bronchos-
copies after lung transplantation [68–70] (B-II). Besides the
early detection of asymptomatic significant acute rejection ep-
isodes or CMV pneumonitis in ∼20%–30% of procedures, it
allows the early identification of cases colonized by Aspergillus.
Regular examination of peripheral blood for CMV by pp65
antigen detection or PCR has become routine in almost all
centers (A-II).
LUNG TRANSPLANT DONOR
Almost all donor lungs harbor microorganisms at the time of
organ procurement [72]. In ∼40% of the recipients, these or-
ganisms can subsequently be isolated, and in ∼20% of them,
bronchopneumonia develops as a result of the respective or-
ganisms [73]. Deaths in lung transplant recipients because of
donor-transmitted bacterial pneumonia have been described
[72]. Thus, the bacteriological examination of bronchial wash-
ings of the donor lung is a prerequisite for the management
of subsequent invasive infection in the transplant recipients (A-
II). Even the growth of normal oral flora in the donor is con-
sidered to be a risk factor for early bacterial pneumonia in the
recipient [14]. We recommend that antibiotic coverage in lung
transplant recipients should be initiated with a broad-spectrum
agent (A-II) and modified on the basis of cultures obtained
from the donor lungs (A-II) [73], except in recipients with
cystic fibrosis, who should be treated with an antimicrobial
combination therapy tailored according to the pretransplant
sputum cultures for ∼2 weeks (A-III), as discussed below. In
1 series, this approach reduced the incidence of early postop-
erative bacterial pneumonia from 33% in a historical control
group to 13% ( ) [13, 14].Pp .005
Fiber-optic bronchoscopy with microbiologic sampling
should be performed routinely in the lung donor [74] (A-III).
The finding of a positive Gram stain, purulent secretions, or
minor infiltrates on the chest X-ray is no obstacle for accepting
the lungs for transplantation [75, 76] (B-II), and the results of
transplantation utilizing these marginal donor organs have
shown to be comparable to those using ideal transplants [77,
78]. Using these lungs for single-lung transplantation in recip-
ients with pulmonary hypertension, however, is not advisable,
because any postoperative allograft dysfunction may result in
profound hypoxemia due to ventilation-perfusion mismatch,
which is much more pronounced than in single-lung trans-
plantations for other diseases [79] (D-III). Significant pneu-
monia and gross aspiration are generally considered to be a
reason for exclusion [78] (E-III). There is experimental evi-
dence that antibiotic treatment of donors with bacterial con-
tamination prevents pneumonia in canine lung recipients [80].
Thus, antimicrobial treatment of human donors may decrease
the risk of early bacterial pneumonia [78] (B-III).
Heavy growth of Candida species in the donor bronchus is
a significant obstacle for accepting the organs for transplan-
tation. The sequelae are mediastinitis, sepsis, or involvement
of the great vessels leading to mycotic aneurysms and consec-
utive rupture. In 1 series, 3 of 4 recipients of lung transplants
with heavy growth of Candida species developed mediastinitis,
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which was uniformly fatal [14]. Thus, such donor organs
should possibly be discarded (D-II). If they are nevertheless
used, antifungal treatment with amphotericin should be insti-
tuted immediately (B-III) [14].
Unused donor lungs in cases of single-lung transplantation
should undergo pathologic analysis (A-II) [81, 82], because they
may show important unexpected findings such as pneumonia,
emphysema, or pulmonary emboli. Moreover, the history of
the donor is important to detect rare donor-related compli-
cations such as bone marrow or brain embolism.
RECIPIENT
Low-dose pretransplant corticosteroid treatment in the recip-
ient has now proved to be acceptable, or even beneficial, and
allows transplantation in patients who cannot be completely
weaned from such therapy [83] (A-II); however, it has to be
taken into account that in the case of single-lung transplan-
tation the remaining native lung may harbor serious oppor-
tunistic infections such as invasive aspergillosis or P. carinii
pneumonia [19, 58]. Thus, it is of the utmost importance to
examine the excised recipient’s lungs pathologically as quickly
and thoroughly as possible (A-III), including microbiological
analysis. If there is an invasive infection present, the transplant
physician should be alerted, especially in the case of single lung
transplantation, because the remaining native lung may harbor
the same infection. The presence of an aspergilloma in the
potential lung transplant recipient is often considered to be a
contraindication for lung transplantation because of the danger
of serious intraoperative bleeding. There are, however, no sound
data on this issue, especially not in the setting of modern sur-
gical techniques (D-III).
Computed tomography of the thorax should be performed
routinely (A-III). It may help to detect mediastinal problems
and intrapulmonary alterations such as abscesses or aspergil-
lomas and other relevant findings with respect to transplant
surgery. Computed tomography of the paranasal sinuses is rec-
ommended in patients with cystic fibrosis in order to detect
invasive infections and potentially to plan pre- or posttran-
splant sinus surgery (A-III).
NATIVE LUNG
Several centers now report complications arising from the re-
maining native lung after single-lung transplantation, such as
severe overinflation, perfusion mismatch, pneumothorax, and
bacterial and fungal pneumonia. The incidence varies between
20% and 50% [8, 12, 19, 57, 84]. Morbidity and mortality are
considerable, and many patients need additional surgery. In-
vasive aspergillosis of the native lungs is the most feared com-
plication and often requires pneumonectomy [85]. The native
lung in patients immunosuppressed during the pretransplant
period, such as in cases of idiopathic pulmonary fibrosis, may
harbor infectious agents such as M. tuberculosis, P. carinii, and
Aspergillus fumigatus, which lead to serious exacerbations after
transplantation.
CYSTIC FIBROSIS
As a consequence of the infectious nature of the pulmonary
disease, the procedure of choice in patients with cystic fibrosis
is double-lung transplantation [86]. Some centers still perform
heart-lung transplantation in these patients with comparable
results. Single-lung transplantation is considered not to be fea-
sible; however, a few patients having undergone this procedure
with concomitant contralateral pneumonectomy have been re-
ported [87]. It is surprising that, despite the common presence
of airway pathogens (P. aeruginosa, S. aureus, Aspergillus spe-
cies) before transplantation, there is no evidence that patients
with cystic fibrosis are at greater risk of infectious complications
because of these organisms after lung transplantation than are
other patients [51, 55, 88].
It has been shown from macrorestriction fragment pattern
similarity that there is no change in the P. aeruginosa population
in the airways of lung transplant recipients before and after
transplantation [89]. Thus, it is assumed that the chronic drain-
age of P. aeruginosa into the lung allografts is caused by the
bacterial reservoir in the paranasal sinuses and the trachea. The
value of pre- or posttransplant sinus surgery in patients with
cystic fibrosis, however, has not yet been established, but this
procedure has been advocated by some centers [90–94] (B-III).
It may reduce posttransplant bacterial infectious complications
as has been shown in nontransplanted patients with cystic fi-
brosis [95].
Some centers consider the presence of a respiratory pathogen
such as P. aeruginosa resistant to all antibiotics or other multiply
resistant bacteria including Burckholderia cepacia, Stenotropho-
monas maltophilia, or Alcaligenes xylosoxidans a contraindica-
tion to lung transplantation; however, this idea is not based on
solid evidence [86]. Synergy testing of antimicrobial pairs in
checkerboard dilutions of clinically achievable drug concentra-
tions may inhibit most of the multiply resistant strains [96].
Patients colonized with B. cepacia are of special concern in 2
ways: first, most series demonstrate an increased posttransplant
morbidity and mortality because of overwhelming pneumonia
or sepsis caused by this organism [94]. Second, transmission
between patients of B. cepacia is well documented [97], and
this may adversely influence the center-specific epidemiological
situation from a microbiological point of view. It seems, how-
ever, that there are different strains of B. cepacia regarding its
aggressiveness and transmissibility. Thus, the decision to accept
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patients with cystic fibrosis colonized by B. cepacia depends on
the center-specific situation [98].
Infection with nontuberculous mycobacteria occurs in some
patients with cystic fibrosis. This seems not to be a contrain-
dication for lung transplantation (B-III), because in most re-
ported cases these organisms can no more be isolated post-
operatively [55].
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